These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19263297)

  • 1. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
    Aksoy S; Dizdar O; Hayran M; Harputluoğlu H
    Leuk Lymphoma; 2009 Mar; 50(3):357-65. PubMed ID: 19263297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of rituximab maintenance therapy in follicular lymphomas.
    Solal-Céligny P
    Leuk Res; 2006 Mar; 30 Suppl 1():S16-21. PubMed ID: 16750674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials.
    Rafailidis PI; Kakisi OK; Vardakas K; Falagas ME
    Cancer; 2007 Jun; 109(11):2182-9. PubMed ID: 17429839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
    Tomás JF; Montalbán C; De Sevilla AF; Martínez-López J; Díaz N; Canales M; Martínez R; Sánchez-Godoy P; Caballero MD; Peñalver J; Prieto E; Salar A; Burgaleta C; Queizán JA; Bajo R; De Oña R; De La Serna J
    Leuk Lymphoma; 2011 Mar; 52(3):409-16. PubMed ID: 21275633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
    Wolach O; Bairey O; Lahav M
    Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
    Ren YR; Jin YD; Zhang ZH; Li L; Wu P
    Chin Med J (Engl); 2015 Feb; 128(3):378-83. PubMed ID: 25635435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
    Eve HE; Linch D; Qian W; Ross M; Seymour JF; Smith P; Stevens L; Rule SA
    Leuk Lymphoma; 2009 Feb; 50(2):211-5. PubMed ID: 19197729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
    Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
    Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
    De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA
    Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
    Martínez-López J; Rivero A; Rapado I; Montalbán C; Paz-Carreira J; Canales M; Martínez R; Sánchez-Godoy P; Fernández de Sevilla A; Peñalver FJ; Gonzalez M; Prieto E; Salar A; Burgaleta C; Queizán JA; Peñarrubia MJ; Monteagudo MD; Cabrera C; De la Serna J; Tomás JF
    Leuk Lymphoma; 2009 Aug; 50(8):1283-9. PubMed ID: 19557622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
    Savage DG; Cohen NS; Hesdorffer CS; Heitjan D; Oster MW; Garrett TJ; Bar M; del Prete S; March R; Lonberg M; Talbot S; Mears JG; Flamm M; Taub RN; Nichols G
    Leuk Lymphoma; 2003 Mar; 44(3):477-81. PubMed ID: 12688318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab as maintenance therapy for patients with follicular lymphoma.
    Vidal L; Gafter-Gvili A; Leibovici L; Shpilberg O
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006552. PubMed ID: 19370640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
    J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The infectious consequences of rituximab addition to fludarabine-containing regimens.
    Tam CS; Seymour JF
    Blood; 2006 Apr; 107(7):3013-4. PubMed ID: 16554491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.